Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
New study illustrates a novel approach to uncovering genetic causes of congenital heart disease in the “dark genome” using AI
Congenital heart disease (CHD) is the most commonly occurring birth anomaly. Despite a strong genetic basis, almost 90% of cases remain genetically undiagnosed. However, the surge of new technology is enabling a search for hidden gene defects not detectable on...ECHO Spotlight Series: Panorama Health Leverages Wearable Technology to Combat Cardiovascular Disease
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...ECHO Spotlight Series: Revolutionizing Cardio-Oncology Care with Leynek Medical
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...ECHO Spotlight Series: AVA
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...ECHO Spotlight Series: Heart Squared’s Next-Generation Ventricular Assist Device
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...New study using stem cells highlights myosin inhibitors as targeted treatment for pediatric hypertrophic cardiomyopathy
Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....Exploring the Heart’s Hidden Layers: Advances in Cardiac Fibroblast Diversity
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles’ fibroblasts. This research, conducted by a team of dedicated scientists from the...Unlocking another piece of the puzzle: novel approach maps signaling pathways underlying heart failure
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...$90-million gift to Ted Rogers Centre for Heart Research marks new era in cardiac health
The Rogers Foundation announces a second landmark gift, building on its $130 million gift in 2014, to sustain the Ted Rogers Centre for Heart Research in perpetuity and bring the promise of precision cardiac health to patients across Canada and globally. In 2014, the...Unravelling the heart-brain connection
Ted Rogers Chair in Heart Function Outcomes Dr. Douglas Lee leads new Heart-Brain Connection $3 million IMPACT Award project